LXEO: Lexeo Therapeutics, Inc. Stock

by  •  • Comments Off on LXEO: Lexeo Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 75.69
Enterprise Value ($M) 40.68
Book Value ($M) 116.84
Book Value / Share 3.52
Price / Book 0.65
NCAV ($M) 96.02
NCAV / Share 2.89
Price / NCAV 0.79

Profitability (mra)
Return on Invested Capital (ROIC) -0.78
Return on Assets (ROA) -0.46
Return on Equity (ROE) -0.54

Liquidity (mrq)
Quick Ratio 5.52
Current Ratio 5.52

Balance Sheet (mrq) ($M)
Current Assets 126.12
Assets 146.94
Liabilities 30.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -105.77
Net Income -98.33

Cash Flow Statement (mra) ($M)
Cash From Operations -81.15
Cash from Investing -94.08
Cash from Financing 88.78

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Omega Fund VI, L.P. 3.60 -45.10
02-14 13G/A Janus Henderson Group Plc 13.10 15.31
02-14 13G/A Eventide Asset Management, Llc 3.73 -33.47
02-13 13G Mizuho Financial Group Inc 5.80
02-12 13G/A Adage Capital Management, L.P. 6.68 -14.94
02-04 13G BlackRock, Inc. 5.50
11-14 13G/A Lundbeckfond Invest A/S 2.90 -48.66
11-14 13G/A Longitude Capital Partners IV, LLC 8.40 7.72

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 130,117 545,998 23.83
2025-04-16 224,257 529,644 42.34
2025-04-15 208,961 637,714 32.77
2025-04-14 186,438 659,333 28.28

(click for more detail)

Similar Companies
LGND – Ligand Pharmaceuticals Incorporated LNTH – Lantheus Holdings, Inc.
LRMR – Larimar Therapeutics, Inc. MDWD – MediWound Ltd.
MIRM – Mirum Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io